InvestorLens

DRTS — ALPHA TAU MEDICAL LTD

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying DRTS?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
67
Institutional Conviction
Net distribution · 2 buying vs 1 selling last quarter
43
Macro Tailwind
Macro conditions are mixed for this sector
56
Why? — Evidence & Confidence ▾

Of 3 tracked investors who changed their DRTS position last quarter, 2 bought and 1 sold (67% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin)
  • +3 tracked investors reported holding DRTS at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About ALPHA TAU MEDICAL LTD (DRTS)

ALPHA TAU MEDICAL LTD (DRTS) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $5M. Across recent filings, tracked investors recorded 4 new positions, 4 increased, 5 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in DRTS

62
/100
Institutional Accumulation
Added / Increased8
Reduced5
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track DRTS

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

DRTS Ownership Composition

How ALPHA TAU MEDICAL LTD is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
58% of tracked value
Institutions
3
tracked investors
Total Reported
$8.4M
combined 13F value
Types2
  • Multi-Strategy / Quant58.5%
  • Growth & Innovation41.5%
Multi-Strategy / Quant(2)
58.5%
Growth & Innovation(1)
41.5%

Tracked investors currently reporting DRTS

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    375.5K
    Value
    $4.7M
    % Portfolio
    0.00%
  • Cathie WoodJun 30, 2026
    ARK Investment Management
    Shares
    277.1K
    Value
    $3.5M
    % Portfolio
    0.02%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    62.3K
    Value
    $183.8K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold DRTS?
3 tracked institutional investors disclosed a position in DRTS (ALPHA TAU MEDICAL LTD) in their most recent 13F filing.
Who is the largest institutional holder of DRTS?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in DRTS, valued at $5M.
Did institutional ownership of DRTS increase or decrease?
Across recent 13F filings, tracked investors recorded 4 new positions, 4 increased, 5 reduced, and 0 fully exited DRTS.
Where does this DRTS ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.